Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification of DHODH as a therapeutic target in small cell lung cancer.

Li L, Ng SR, Colón CI, Drapkin BJ, Hsu PP, Li Z, Nabel CS, Lewis CA, Romero R, Mercer KL, Bhutkar A, Phat S, Myers DT, Muzumdar MD, Westcott PMK, Beytagh MC, Farago AF, Vander Heiden MG, Dyson NJ, Jacks T.

Sci Transl Med. 2019 Nov 6;11(517). pii: eaaw7852. doi: 10.1126/scitranslmed.aaw7852.

PMID:
31694929
2.

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.

Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A.

Nature. 2015 Jan 22;517(7535):489-92. doi: 10.1038/nature13898. Epub 2014 Nov 2.

3.

Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

To MD, Rosario RD, Westcott PM, Banta KL, Balmain A.

Oncogene. 2013 Aug 22;32(34):4028-33. doi: 10.1038/onc.2012.404. Epub 2012 Sep 3.

4.

The genetics and biology of KRAS in lung cancer.

Westcott PM, To MD.

Chin J Cancer. 2013 Feb;32(2):63-70. doi: 10.5732/cjc.012.10098. Epub 2012 Jul 2. Review.

5.

Dual inactivation of Hus1 and p53 in the mouse mammary gland results in accumulation of damaged cells and impaired tissue regeneration.

Yazinski SA, Westcott PM, Ong K, Pinkas J, Peters RM, Weiss RS.

Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21282-7. doi: 10.1073/pnas.0904965106. Epub 2009 Nov 16.

Supplemental Content

Loading ...
Support Center